Literature DB >> 17413422

Misleading findings of homozygosity mapping resulting from three novel mutations in NPHS1 encoding nephrin in a highly inbred community.

Yaacov Frishberg1, Ziva Ben-Neriah, Maija Suvanto, Choni Rinat, Minna Männikkö, Sofia Feinstein, Rachel Becker-Cohen, Hannu Jalanko, Joel Zlotogora, Marjo Kestilä.   

Abstract

PURPOSE: Congenital nephrotic syndrome of the Finnish type (CNF, NPHS1) is a rare autosomal recessive disease caused by mutations in the NPHS1 gene encoding nephrin. We diagnosed congenital nephrotic syndrome in 12 children living in a village near Jerusalem. Most of the inhabitants are descendants of one Muslim family and have maintained their isolation by preference of consanguineous marriages. The aim of this study was to confirm that the NPHS1 gene is responsible for congenital nephrotic syndrome in our population, applying homozygosity mapping.
METHODS: DNA samples were genotyped by four microsatellite markers that were in linkage disequilibrium with the NPHS1 gene on chromosome 19q13.1. Immunoperoxidase staining was used to study the expression of nephrin, and mutations were subsequently identified by direct sequencing of the entire coding region of the NPHS1 gene.
RESULTS: Haplotype analysis revealed several different haplotypes, leading us to assume erroneously that there was genetic heterogeneity of congenital nephrotic syndrome. Because nephrin was completely absent in kidney tissue of one patient, direct sequencing of all DNA samples was performed, yielding three novel mutations: c.1138C>T (p.Gln380X), c.2160_ 2161insC (p.Cys721fs), and c.1707C>G (p.Ser569Arg). Patients were either homozygous for one of these mutations or compound heterozygotes, and they differed in their phenotype.
CONCLUSION: We report the potential pitfalls of performing homozygosity mapping in a highly consanguineous population and discuss the phenomenon of multiple mutations in a given gene within an isolate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413422     DOI: 10.1097/gim.0b013e318031c7de

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  6 in total

1.  Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome.

Authors:  Eduardo Machuca; Geneviève Benoit; Fabien Nevo; Marie-Josèphe Tête; Olivier Gribouval; Audrey Pawtowski; Per Brandström; Chantal Loirat; Patrick Niaudet; Marie-Claire Gubler; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 10.121

2.  A targeted population carrier screening program for severe and frequent genetic diseases in Israel.

Authors:  Joël Zlotogora; Rivka Carmi; Boaz Lev; Stavit A Shalev
Journal:  Eur J Hum Genet       Date:  2008-12-24       Impact factor: 4.246

3.  Novel mutations in steroid-resistant nephrotic syndrome diagnosed in Tunisian children.

Authors:  Ibtihel Benhaj Mbarek; Saoussen Abroug; Asma Omezzine; Audrey Pawtowski; Marie Claire Gubler; Ali Bouslama; Abdelaziz Harbi; Corinne Antignac
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

Review 4.  The molecular basis of autosomal recessive diseases among the Arabs and Druze in Israel.

Authors:  Joël Zlotogora
Journal:  Hum Genet       Date:  2010-09-18       Impact factor: 4.132

5.  Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications.

Authors:  Ruth Bargal; Valerie Cormier-Daire; Ziva Ben-Neriah; Martine Le Merrer; Jacob Sosna; Judith Melki; David H Zangen; Sarah F Smithson; Zvi Borochowitz; Ruth Belostotsky; Annick Raas-Rothschild
Journal:  Am J Hum Genet       Date:  2008-12-24       Impact factor: 11.025

6.  Increased Probability of Co-Occurrence of Two Rare Diseases in Consanguineous Families and Resolution of a Complex Phenotype by Next Generation Sequencing.

Authors:  Dennis Lal; Bernd A Neubauer; Mohammad R Toliat; Janine Altmüller; Holger Thiele; Peter Nürnberg; Clemens Kamrath; Anne Schänzer; Thomas Sander; Andreas Hahn; Michael Nothnagel
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.